- Video Center
- Social Media
- Media Contacts
Leverkusen, April 24, 2020 – Based on a protocol signed with the AIFA (Italian Medicines Agency), Bayer will donate approximately one million chloroquine tablets for COVID-19 treatment in Italy.
AIFA’s Technical-Scientific Commission added chloroquine, along with other drugs, to the list of medicines for so-called off-label use outside of the established indications to treat patients with COVID-19 on March 13, 2020. In addition, chloroquine was officially included in the so-called Vademecum for the treatment of people affected by the COVID-19 disease, 2.0 version, released by the Italian Society of Infectious and Tropical Diseases (Simit) on March 13, 2020.
“In these difficult times, Bayer is committed to helping patients around the world. This includes unprecedented collaboration with all our stakeholders including other pharmaceutical companies,” said Dr. Franco Pamparana, Head of the Medical Department of Bayer Italy.
In light of the global COVID-19 pandemic, Bayer is supporting a number of governments to treat patients suffering from SARS-CoV-2 infection and to help ease the pressure on overwhelmed health systems. The company is exclusively donating chloroquine to health authorities to allow for coordinated and supervised emergency use of Chloroquine outside of the established indications, as prescription medicines should only be used under the guidance of a physician. It is important to note that there is no clinically proven evidence for a positive benefit-risk ratio of chloroquine as a possible COVID-19 treatment option yet available.
Bayer is the manufacturer of chloroquine, a malaria drug which the Chinese health authorities have also included in their treatment recommendations for COVID-19, outside of the EU.
Bayer is supporting the worldwide fight against the corona pandemic with its products, technical equipment, know-how and the engagement of its employees. You can find a current overview here: https://www.bayer.com/en/coronavirus-covid-19-update.aspx .
A digital press kit is available at: https://www.media.bayer.com/baynews/baynews.nsf/id/presskit-corona
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Follow us on Twitter: twitter.com/Bayer
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center